What Buflo Treats: Main Uses and Benefits

Buflomedil is commonly used to help manage symptoms associated with certain vascular disorders. It is relevant for easing symptoms in conditions presenting with chronic reduction in blood flow, such as peripheral arterial disease (PAD) and chronic arterial occlusive disease, as well as some symptoms linked to cerebrovascular insufficiency.

The support provided by this medication helps ease the overall symptom burden, including physical discomfort and functional strain associated with these conditions. It is applied in addressing symptom clusters that may become intense or disruptive, such as intermittent claudication (exercise-induced leg pain), ischemic rest pain, and trophic skin disorders related to severe ischemia. This support helps maintain a sense of stability when symptoms are more noticeable and contributes to improved day-to-day comfort.

“This medication assists with maintaining functional stability and provides supportive relief when symptoms interfere with routine activities.”

---

Quick Fact: Support for Vascular Discomfort Buflomedil may be part of symptomatic management for chronic physical discomfort in the limbs and can help improve day-to-day comfort during symptomatic periods.

The eligibility profile for Buflomedil (Buflo) is strictly defined by regulatory authorities and includes several absolute exclusions due to the drug’s toxicity risks. The medicine is primarily authorized for use in adults requiring symptomatic treatment for Stage II Peripheral Arterial Occlusive Disease (PAOD).

Populations for Whom Use is Contraindicated

Buflomedil is officially contraindicated and must not be used by:

• Patients with a history of convulsions or epilepsy.
• Patients with severe renal impairment (Creatinine Clearance less than 30 mL/min).
• Patients with known hypersensitivity to the active substance or any excipients.

Restricted and Non-Recommended Use

Regulatory documentation classifies use as not established or not recommended for:

• Pediatric population (children and adolescents).
• Pregnant women and lactating women.

Use in older adults or patients with moderate renal impairment requires specific caution and close monitoring. These restrictions are imposed because the drug has a narrow therapeutic index, meaning even slightly impaired kidney function can dramatically increase the risk of serious adverse effects.

Interactions with other medicines and products

Official regulatory documentation for Buflomedil specifies interaction patterns focused on pharmacodynamic effects and administration requirements.

Documented Interaction Classes

The co-administration of Buflomedil with Alcohol (Ethanol) is formally prohibited. This restriction is documented due to the significant risk of an additive pharmacodynamic effect, specifically an augmentation of Central Nervous System (CNS) depression, leading to outcomes such as somnolence.

Combining Buflomedil with other CNS Depressants (such as sedatives or anxiolytics) may result in an increased risk of somnolence and dizziness, which is officially described as an additive CNS depressant effect. Similarly, co-administration with Antihypertensive Agents and other Vasodilators may lead to an additive hypotensive effect, enhancing the reduction in blood pressure.

Administration and Population-Specific Notes

A specific administration requirement is documented: Buflomedil must be taken on an empty stomach. This constraint addresses a formal drug-food interaction that affects the product's absorption and resulting exposure profile.

Regulatory documents note population-specific considerations regarding interactions. Elderly Patients are considered more sensitive to documented CNS and cardiovascular pharmacodynamic interactions. Furthermore, the risk of enhanced or prolonged interaction effects is noted for Patients with Hepatic Impairment, a population where Buflomedil clearance may be compromised.

How Buflo Works

Buflomedil's mechanism is defined by a dual action that physically widens peripheral blood vessels while simultaneously modulating the physical flow properties of the blood components. This coordinated effect increases microcirculatory transport capacity.

---

Modulation of Autonomic Vascular Tone

Buflomedil primarily functions as an alpha-adrenoceptor antagonist, interrupting the vasoconstrictive signaling exerted by the sympathetic nervous system on peripheral arteries. By blocking these receptors and acting as a calcium channel modulator, the molecule directly induces vascular smooth muscle relaxation

. This fundamental mechanistic action decreases the force opposing blood flow, leading to a reduction in peripheral vascular resistance.

Hemorheological Modulation and Microcirculatory Dynamics

The second core mechanism involves direct influence over the physical properties of blood components. Buflomedil increases the deformability of red blood cells (RBCs), allowing for increased flexibility in narrow capillaries. This action is complemented by an anti-platelet effect that decreases clumping and blood viscosity. The resulting physiological effect is an enhanced modulation of blood flow dynamics, influencing the distribution of blood volume to the capillary level.

How Buflo is Used: Official Dosing and Administration

This section details the authorized principles for administering Buflo (buflomedil hydrochloride) in clinical practice, adhering strictly to prescribing information regarding route, dosage, frequency, and preparation.

---

Official Routes of Administration and Forms

Buflo is administered using two main methods, consistent with its availability in different formats:

• Oral Administration: The medication is taken by mouth using tablets (standard or prolonged-release forms).
• Parenteral Administration (Injection): It is administered as a solution for injection via the intramuscular (IM) or intravenous (IV) routes, often in a supervised setting for initial therapy before transitioning to oral use.

Standard Adult Dosing and Frequency

Oral Dosing: The usual total daily dose ranges from 300 mg to 600 mg for adults with normal renal function. This dose is typically administered in at least two divided doses per day (e.g., two or three times daily) to avoid administering the full amount at once. Tablets may generally be taken with or without food.

Maximum Daily Dose: The maximum recommended oral dose is 600 mg per day for patients with normal kidney function.

Use Patterns and Special Instructions

Area of Instruction	Official Guidance
Initiation of Therapy	The injectable form (IM or IV) is frequently used to initiate therapy for a short course, followed by a switch to the oral form for long-term management.
Dose Adjustment	For patients with mild to moderate renal failure (creatinine clearance 30 to 80 ml/min), the maximum daily oral dosage must be reduced by half, not to exceed 300 mg.
IV Administration	The intravenous solution should be administered slowly, and typically requires dilution in an appropriate isotonic solution for infusion.

Research Evidence / Overview of Studies for Buflo

This section provides an overview of the types of official research available for Buflomedil, the populations and conditions studied, the outcomes measured, and the overall quality or consistency of the evidence, as described by regulatory and scientific reviews.

---

Evidence for Use in Peripheral Arterial Disease (PAD) Symptoms

Research exploring Buflomedil was evaluated in conditions characterized by functional limitations, such as intermittent claudication (leg pain during walking due to reduced blood flow). The evidence includes both older, small-scale clinical trials and later, larger, longer-term studies. These studies monitored outcomes reflecting daily functioning or activity level.

Early research involved numerous Randomized Controlled Trials (RCTs). These short-term studies monitored patient-reported outcomes describing perceived discomfort and functional measures like the increase in pain-free walking distance (PFWD) and maximum walking distance (MWD) on a treadmill. Some trials described patterns observed in these walking distance measurements. Reviewers noted that the findings were mixed and highly variable across different studies. Regulatory bodies have cited that the evidence quality varies across studies, noting that many early trials had sample sizes that were modest.

A later, large-scale study monitored patients over several years. This study examined composite vascular outcomes (a combination of major events such as cardiovascular death or nonfatal stroke) in addition to functional measures like walking ability. This long-term research contributes to the broader evidence landscape, reflecting group patterns, and does not determine whether an individual will respond similarly. Due to the variability and limitations in the initial studies, certainty regarding the observed changes in symptom patterns remains low.

---

Evidence for Use in Cerebrovascular Insufficiency

Buflomedil was studied for conditions associated with acute or disruptive episodes, specifically following an acute ischemic stroke. This research primarily involved small Randomized Controlled Trials (RCTs) conducted in specific geographical regions. These trials explored short-term symptom changes and examined neurological function using specialized scales to look for patterns related to deficits. Available systematic reviews describe patterns related to neurological function that were highly inconsistent across studies. Because many of these trials were noted to have methodological flaws and poor reporting, the evidence base for this condition is also considered limited.

---

What is Still Uncertain About the Research for Buflo

The research surrounding Buflomedil highlights areas where the evidence is limited and where further studies would be necessary to establish certainty. Across both studied indications, the evidence quality varies across studies, with many older trials having small sample sizes and potential methodological concerns. Furthermore, the data for certain groups, such as those with certain comorbidities or specific levels of disease severity, remain insufficient. Research provides context but highlights what is known — and what is still uncertain — about the full picture of Buflomedil’s evaluation.

Common questions about Buflo (FAQ)

Q: How long does it take for Buflomedil to start working (onset of action)?

Official pharmacokinetic studies show that the medicine reaches its maximum concentration in the bloodstream approximately 1.5 hours after taking an oral dose. This measurement of concentration does not necessarily reflect the time it takes for a patient to notice the clinical effects, which can vary widely among individuals.

Q: What are the known long-term side effects of Buflomedil?

Regulatory reviews of the medicine have highlighted serious concerns regarding neurological and cardiac side effects, including reports of convulsions and cardiac arrest. These risks were observed even at typical doses, which led to regulatory action in certain regions, underscoring the serious nature of the known risks associated with the drug.

Q: What is the half-life of Buflomedil?

According to official pharmacokinetic data, the drug Buflomedil has an overall elimination half-life of approximately 2 to 3.3 hours following oral administration. The half-life describes the time required for the amount of medicine in the body to decrease by half.

Q: What are the excipients/inactive ingredients, and do they pose a risk for allergies?

Official product information is required to explicitly list all excipients, which are the inactive ingredients in the tablet or capsule. These documents also highlight any excipients with known effects that may potentially cause an allergic or hypersensitivity reaction in some individuals.

Q: Why was Buflomedil discontinued in some countries?

The European Medicines Agency (EMA) recommended the suspension of all buflomedil-containing medicines in the European Union. This regulatory action was taken because the serious risks of neurological and cardiac side effects were found to outweigh the drug's limited clinical benefits.

Q: What are the available strengths of the Buflomedil tablet?

Regulatory documents in various regions mention the marketing of 150 mg tablets, which is one of the forms available. Official product information describes that the dose range for adults with normal kidney function extends up to 600 mg daily.

Q: Does Buflomedil affect blood sugar levels?

While studies have examined Buflomedil in subjects who have diabetes, the official regulatory documents do not contain explicit statements that the drug directly or significantly changes a patient's blood sugar levels. Individuals with diabetes should discuss their full treatment plan with their healthcare provider.

Q: How long does the effect of Buflomedil last?

Official pharmacokinetic data indicate that the overall elimination half-life is between 2 and 3.3 hours. The half-life is the time it takes for the concentration of the drug in the body to be reduced by half, which provides context on how long the medicine remains in the system.

Q: Have there been any recent safety changes or warnings for Buflo?

Yes, the European Medicines Agency (EMA) has recommended the suspension of all oral buflomedil-containing medicines. This major safety review was based on findings that indicated the risks of serious cardiological and neurological side effects outweighed the drug's benefits.

Q: Are there any religious or cultural concerns with the ingredients (excipients, e.g., gelatine)?

The official product documentation, such as the Summary of Product Characteristics (SmPC), is required to list all inactive ingredients, known as excipients. This allows individuals to review the composition against any specific religious or cultural dietary requirements they may have.

Q: Why is Buflo sometimes mentioned in discussions about chronic pain?

Research evidence for Buflo examined its use in patients with Peripheral Arterial Disease (PAD) to improve functional limitations like intermittent claudication. Intermittent claudication is specifically defined as leg pain that occurs during walking due to reduced blood flow, which is the link to discussions involving pain.

How to Store and Dispose of Buflo (Buflomedil hydrochloride)

Storage and disposal must strictly follow the official instructions provided by the regulatory agency.

---

Storage and Handling

Buflo must be stored out of the sight and reach of children to prevent the risk of accidental ingestion. The medication should be kept in a tightly closed container and stored in a dry place to maintain its stability. Specific temperature requirements are listed on the product insert and must be followed.

Disposal Instructions

Do not dispose of unused or expired Buflo in household trash or down a sink or toilet. Disposal must be conducted in accordance with local/regional/national/international regulations for pharmaceutical waste. Patients are instructed to utilize authorized drug take-back programs or consult a pharmacist for guidance, ensuring the product does not contaminate the sewage system or ground water.